TargetBeta
FCGR2B
Fc gamma receptor IIb · also CD32, CD32B, FcgammaRIIb, FcGRIIB · CD molecules
2 programs in company-led studies act on FCGR2B, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| obexelimab | Zenas BioPharma (USA) | phase 3 | 74 running | CD19 | a judged reading |
| Anti-CD32B Monoclonal Antibody BI-1607rule | BioInvent International AB | phase 2 | 21 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Anemia, Hemolytic, Autoimmune, 1 program
- Breast Neoplasms, 1 program
- Immunoglobulin G4-Related Disease, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Multiple Sclerosis, 1 program
- Uveal Melanoma, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.